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Abstract
The major histocompatibility complex (MHC) is a polymorphic gene cluster of about 
150 genes, present in all vertebrates. Many of these genes contribute to immunity. 
Particularly, MHC‐encoded class I and class II molecules, which are typically highly 
polymorphic and polygenic, are central in defining the specificity of the adaptive immune 
response. Among the diversity of genes associated with disease resistance, MHC genes 
are particularly interesting as they are associated with resistance and susceptibility to a 
wide range of diseases, some of which produce important economic losses in livestock. 
Enzootic bovine leukosis is an infectious disease caused by the retrovirus bovine leuke‐
mia virus (BLV), with an important economic impact, mainly in dairy herds. In this chap‐
ter, MHC‐associated genetic resistance to BLV is revised. Certain alleles of the bovine 
MHC (BoLA) class II locus have been found strongly associated with resistance to viral 
dissemination. Genetic selection of resistant animals emerges as a natural strategy for the 
control of infectious diseases, especially when there is no other alternative of control or 
prevention, as vaccines. Founded on this knowledge, a BLV control program based on 
selection of genetically resistant cattle was designed. The proof of concept indicates that 
this strategy is feasible to implement in dairy herds.
Keywords: major histocompatibility complex, BoLA, genetic resistance, infectious 
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1. Introduction
The immune system has evolved in vertebrates to protect them from invading pathogens. 
To attain this objective, it compromises an enormous variety of cells and molecules that inter‐
act with each other in a complex network to recognize, counteract, and, if properly regulated, 
eliminate the pathogen. The major histocompatibility complex (MHC), which is found to 
occur in all mammalian species, plays a central role in the development and function of the 
immune system. Genes encoding the MHC are highly polymorphic, and numerous associa‐
tions between allelic variants and immune responsiveness and disease resistance are well 
documented. Hence, the MHC genes are attractive as candidate genes involved in suscepti‐
bility/resistance to various diseases.
Breeding for improved disease resistance has emerged as a major challenge for animal geneti‐
cists. The benefits of successfully improving the resistance of animals to an infectious disease 
are manifold, including animal welfare, increased efficiency and productivity, and hence a 
reduced environmental footprint, reduced reliance on other disease‐control measures, and 
improved public perception [1].
Enzootic bovine leucosis is an endemic disease in many countries, causing important eco‐
nomic impact in the dairy industry. The fine characterization of the resistance phenotype, the 
strong association between certain MHC class II alleles with resistance, and the absence of 
preventive or therapeutic measures against the disease make the genetic selection of resistant 
animals a feasible approach to control bovine leukemia virus (BLV) infection.
2. The major histocompatibility complex
Vertebrates have the capacity to recognize, destroy, and develop immunological memory 
to invading microorganisms through the activation of cells and molecules of their immune 
system. In order to achieve these ends, the two arms of the immune system (i.e., the innate 
and the acquired immunity) have to interact with each other. The innate immune system 
comprises mainly cells from the myeloid lineage that recognize common structures on a 
broad spectra of microorganisms, known as the pathogen‐associated molecular patterns 
(PAMPs) through their pathogen recognition receptors (PRRs). Some of these cells, like 
macrophages and dendritic cells, are also involved in the activation of the adaptive immune 
system, by capturing and processing the antigens and acting as antigen presenting cells 
(APC) for T lymphocytes.
The effector cells of the adaptive immune system, consisting of B and both helper T lympho‐
cytes (LTH) and cytotoxic T lymphocytes (CTL), recognize a very large variety of self and 
nonself antigens in a more specific manner by their antigen receptors (BCR and TCR, respec‐
tively). The BCR can bind directly to free or soluble native antigen, while the TCR requires 
the protein antigen to be processed into small peptides. These peptides have to be associated 
within the endoplasmic reticulum with molecules encoded by a single genetic locus contain‐
ing many polymorphic genes, the MHC. The assembled MHC molecule (mMHC)‐peptide 
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complex is then transported to and expressed on the surface of the APCs, where the anti‐
gen‐loaded mMHC interacts with the TCR and initiates the activation of T lymphocytes 
[2]. The CTL and the LTH recognize antigen in the context of two different mMHCs: class I 
and class II, respectively. The class II mMHCs have a restricted expression, mainly on pro‐
fessional APCs, and expose peptides mainly derived from captured extracellular antigens 
for the recognition by the LTH. The class I mMHCs are displayed on the surface of every 
nucleated cell of the organism, presenting peptides essentially originated from intracellular 
proteins (i.e., intracellular microorganisms or cell‐derived proteins) to be recognized by the 
CTLs. The class I mMHC does not only play a fundamental role in the recognition of foreign 
intracellular antigens but also in inducing self‐tolerance and alloreactive immune responses.
2.1. Structure of class I and class II MHC molecules
Most of the current knowledge about these molecules arose from pioneer studies on the rejec‐
tion of normal and malignant transplanted tissues in mice and rabbits [3–6]. The evidence 
produced by these studies indicated that the destruction of the grafted tissue was determined 
upon the existence of inherited antigenic differences between transplant and host, leading to 
the discovery of the mMHC and, later on, their genetic complexity.
The mMHCs have different domain organizations but similar structure. The variations are 
concentrated in three to four discrete hypervariable regions in the extracellular domains, 
while the rest of the molecule is highly conserved. The X‐ray crystallography of the proteins 
demonstrated that the class I mMHC is a heterodimer consisting of a transmembrane α chain 
non‐covalently linked to a small non‐transmembrane chain, called β2‐microglobulin (β2m). 
Besides a transmembrane and an intracellular region, the α chain has three extracellular glob‐
ular domains (α1, α2, and α3). The α1 and α2 domains of the α chain form a groove that 
accommodates an 8‐ to 10‐mer antigenic peptide [7, 8]. The class II mMHC is a heterodimer 
composed of an α and a β chain, both with an intracellular, a transmembrane, and two extra‐
cellular domains (Figure 1A). The pairing of the α1 and β1 domains form an antigen‐binding 
groove with open ends, allowing the allocation for a larger peptide (14‐mer or more) extend‐
ing out of both sides of the groove [9] (Figure 1B).
The polygenic and polymorphic features of the MHC grant these molecules with an enormous 
capability for antigen presentation. A single individual co‐expresses several mMHCs from a 
large pool of alleles within a population. Moreover, each mMHC molecule can associate with a 
great amount of similar peptides, expanding even more the breadth of MHC‐regulated immune 
responses to pathogens. The polymorphic residues in the mMHC antigen‐binding groove are 
responsible for the different peptide specificities of the different alleles. The class I molecules 
require an allele‐specific peptide length and a defined peptide motif that includes two anchor 
amino acids or residues with closely related side chains, which interact with both ends of the 
antigen‐binding site of that particular mMHC [10]. The class II mMHCs have less stringency 
for size but also have allele‐specific peptide motifs (or anchor residues) that reach into pockets 
within and on the sides of the groove of the class II mMHC [11] (Figure 1B). Moreover, con‐
served residues within the class II peptide‐binding groove induce a conformational change, forc‐
ing bound peptides into a twisted configuration and exposing sites for external interactions [12].
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2.2. Organization of the Major Histocompatibility Complex
Since its first description in mice and humans [5, 13], the study of the MHC genetic archi‐
tecture has expanded substantially, with the discovery and characterization of many class I 
and class II genes in different vertebrate species, except for jawless fish [14]. The collective 
name given to the proteins encoded by MHC genes depends on the species, except for mice 
and chickens, in which they were first described as transplantation antigens and maintain 
their original nomenclature H‐2 and B, respectively. Hence, in humans, they are called human 
leukocyte antigen (HLA); in swine, SLA; in ovine, OLA; in equine, ELA; in dogs, DLA; in 
bovine, BoLA; and so on. The genetic structure of the MHC is best known for HLA and is 
relatively conserved among other mammalian species [15].
The HLA complex covers about 4 Mb of the short arm of chromosome 6 and contains three 
major regions with the confirmed presence of more than 260 loci, including over 160 protein‐
coding genes [16, 17].
The HLA locus is divided into three closely linked regions: class I, class II, and class III. The 
first two regions contain genes that control the specific immune response (so‐called “classi‐
cal” MHC genes), and the class III region, enclosing about 75 genes, encodes a variety of dif‐
ferent proteins, some related to the innate immunity [18].
Figure 1. Structure of MHC molecules and its binding sites. Panel A: schematic representation of class I and class II 
mMHCs. Panel B. MHC peptide‐binding sites. Amino acid positioning within the peptide‐binding grooves of class I 
and class II MHC proteins is shown. Squares represent individual amino acids of the antigenic peptides binding in the 
groove of each class I and class II mMHC.
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The class I region contains three classical genes, HLA‐A, HLA‐B, and HLA‐C, and three non‐
classical genes: HLA‐E, HLA‐F, and HLA‐G [19] (Figure 2). Each of the classical HLA is a single 
functional gene, encoding a class I mMHC α chain. The gene coding for the β2m is located 
outside the MHC, on chromosome 15. HLA‐H, HLA‐J, HLA‐K, and HLA‐L are nonfunctional 
pseudogenes, closely related in nucleotide sequence to the class I functional genes [18].
The class II HLA cluster comprises three classical class II genes: HLA‐DP, HLA‐DQ, and HLA‐
DR, each encoding one α and one or two β chains; three nonclassical, non‐polymorphic class II 
genes; HLA‐DM, HLA‐DN, and HLA‐DO; and some pseudogenes [19] (Figure 2). These nonclas‐
sical class II genes are not expressed on the cell surface, but form heterotetrameric complexes 
involved in catalytic peptide exchange and loading onto classical class II molecules [20, 21].
The class III region is located between the class I and class II regions and contains genes cod‐
ing for molecules with diverse function. Among the most prominent are the complement 
factor genes coding for factors C2, C4, and B; genes coding for cytokines belonging to the 
tumor necrosis factor (TNF) superfamily, TNF‐α, lymphotoxin‐α and lymphotoxin‐β, which 
are involved in various inflammatory pathways; heat shock protein genes; and many other 
genes encoding proteins not related to the immune system [19].
2.3. The major histocompatibility complex in cattle
In cattle, the first evidence for the existence of a MHC system was found by lymphocyte 
immunizations and by the generation of monospecific antilymphocyte antisera against skin 
grafts, followed by studies on the inheritance of the antigens they detected [22, 23]. As in the 
human, the BoLA locus is highly complex and contains about 154 predicted functional genes 
spanning about 4 centimorgan on chromosome 23 [24]. Figure 2 shows the BoLA  organization 
Figure 2. An abridge map of the genetic organization of HLA and BoLA.
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compared to its human counterpart. Compared to the HLA system, the BoLA system dif‐
fers in gene arrangement without compromising its functions. Class I genes are clustered in 
two regions: BoLA‐A and BoLA‐B. Only the A locus seems to be functional with at least six 
putative classical class I genes, named genes 1–6 [25]. To date, 96 BoLA‐A alleles are listed on 
the Immuno Polymorphism Database (IPD)‐MHC database [26], and 29 different haplotypes 
have been identified, expressing between one and three combinations of these classical class 
I genes [27, 28]. The nonclassical BoLA class I genes include NC1, NC2, and NC3, encoding 
molecules with a relevant role during reproduction in dairy cows [29].
The main difference between BoLA and HLA gene organization is that in cattle the class II 
gene cluster is divided into two subregions, separated about 15 cM apart from each other: the 
class IIa, located near the class I/III regions, and the class IIb, resulting from a transposition, 
located close to the centromere on autosome 23 [30, 31]. This feature is shared by various 
ruminant species [32].
The subregion IIa incorporates the gene clusters DR and DQ but lack a DP gene [27]. This 
subregion expresses one DR molecule and one or two DQ molecules per haplotype [33]. 
Bovines have one monomorphic DRA gene. By contrast, there are three genes that encode for 
the β chain of the DR (DRB) molecule of which DRB1 is a pseudogene and DRB2 is poorly 
expressed, leaving the DRB3 locus as the most polymorphic and strongly expressed gene 
from this group. To date, 130 alleles have been identified using different approaches in vari‐
ous breeds of cattle (listed in IPD‐MHC database) [34].
The DQ cluster comprises five DQA (DQA 1–5) and five DQB (DQB 1–5) genes, which have 
arisen from gene duplication. From this cluster, at least 61 BoLA DQA and 81 BoLA DQB alleles 
have been described and listed in the IPD‐MHC database, and 56 different haplotypes were 
described in Japanese Black and Holstein cattle [35]. The high number of different alleles, both 
on the DR and DQ loci, suggests that DR and DQ molecules complement each other for the 
presentation of a broad spectrum of antigens in cattle.
The BoLA class IIb locus is divided into two regions. The region known as “extended class II” 
region contains some genes involved in antigen processing and transport, i.e., LMP complex (low 
molecular mass polypeptide, LMP2, LMP7) and TAP genes (transporter associated with antigen 
processing: TAP2.1, TAP1, and TAP2) and also some non‐MHC genes like H2B (histone H2B‐like), 
among others [36–38].The second region is known as “classical class II” region and encloses genes 
of unknown function and unique to ruminants: DSB (DRβ‐like), DYA, and DYB. The DYA and DYB 
genes encode for proteins of 253 and 259 amino acids, respectively. DY molecule has been shown 
to be expressed by a subpopulation of afferent lymph dendritic cells, suggesting its involvement 
in the prominent antigen processing and presentation capability of these cells [39–41].
2.4. Association of the major histocompatibility complex to disease susceptibility and 
resistance
Although age, stress, and physiologic status are important factors influencing the outcome of 
infection, evidence for genetic control has been observed in many animal species. Based on 
data registered in the Domestic Animal Diversity Information System (DAD‐IS) 2015 report 
[42], 483 mammalian breed populations are recorded as having resistance or tolerance to 
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 specific diseases or parasites, among which 236 correspond to breeds of cattle, 94 breeds of 
sheep, 56 breeds of chicken, 54 breeds of goats, and 36 breeds of pigs.
Not unexpectedly, the high degree of genetic polymorphism in the MHC has been associated 
with health status, vaccine responsiveness, and production traits in cattle [43–47]. Examples 
of some studies for which there is documented evidence of MHC association with resistance 
or susceptibility to disease include mastitis in cattle and sheep [44, 48], tick‐borne disease 
[49–51], dermatophilosis in cattle [52], enzootic bovine leucosis in cattle and sheep [53–56], 
neosporosis in cattle [57], theileriosis in cattle [58], gastrointestinal parasites in sheep [59, 60], 
diarrhea in pigs [61, 62], Marek's disease in chicken [63, 64], coccidiosis in chicken [65], and 
coronavirus resistance in chickens [66], among others.
3. Enzootic bovine leukosis and the bovine leukemia virus
Enzootic bovine leukosis is one of the most frequent neoplastic diseases of cattle caused by an 
exogenous retrovirus designated BLV. BLV is the type species of the genus Deltaretrovirus in 
the Retroviridae family. This genus also includes pathogenic viruses from human and nonhu‐
man primates (human and simian T‐cell leukemia viruses) that share biological and molecu‐
lar characteristics with BLV [67].
BLV infection is globally distributed in cattle‐raising countries. An assessment of BLV infec‐
tion in US dairy operations in 2007 showed that 83.9 % of them were seropositive for BLV [68]. 
A national study of BLV infection in Canada in 1980 showed that 40 % of its dairy herds and 
11 % of its beef herds were infected [69]. On the other hand, BLV control programs have been 
established in member countries of the European Union since the 1980s, resulting in serop‐
revalence between 0.5 and 1.5 % in some countries, while others such as Belgium, Denmark, 
Germany, Estonia, Spain, France, Ireland, Austria, Finland, Sweden, the United Kingdom, 
and few others are considered officially free by the European Community [70–72].
In natural conditions BLV only infects cattle, zebus, buffalos, and capybaras, but other species 
such as sheep, goats, and rabbits can be experimentally infected [73]. Although both beef and 
dairy breeds are equally susceptible to BLV infection [74], the impact is higher in dairy herds, 
mainly because of differential management practices.
The major target of the virus is the B lymphocyte [75]. Although evidence of infection of 
other peripheral blood cell subpopulations has been reported [76], these results have not been 
confirmed by others. Soon after infection of a cell, the viral RNA is copied into DNA by the 
virus‐encoded reverse transcriptase. The provirus then integrates into the cellular DNA at 
random sites, and the infection persists for the whole life of the animal, despite the presence 
of neutralizing and other antiviral antibodies.
3.1. Pathological and clinical features associated to BLV
BLV infection is characterized by the “iceberg principle,” typical of many viral diseases. 
While the majority (approximately 70 %) of infected cattle remain asymptomatic, one third of 
infected cattle develop a permanent increase in the number of B lymphocytes termed  persistent 
Major Histocompatibility Complex-Associated Resistance to Infectious Diseases: The Case of Bovine Leukemia...
http://dx.doi.org/10.5772/65804
107
 lymphocytosis (PL), which is considered a benign condition. The tip of the iceberg is repre‐
sented by those animals that develop the neoplastic disease, which is usually less than 5 % of 
the infected cattle. The accumulation of transformed lymphocytes in one or more organs after 
a long latency period of 1–8 years leads to a multicentric lymphosarcoma. This condition is 
typically observed in cattle older than 3 years of age. In two thirds of the animals, the develop‐
ment of tumors is preceded by a phase of PL. Lesions can be localized in almost any organ, but 
the abomasum, heart, visceral and peripheral lymph nodes, spleen, uterus, and kidneys are 
most frequently affected. Lesions can be observed as white firm tumor masses or as a diffuse 
tissue infiltrate in any organ. Clinical signs are variable and depend on the affected organ, the 
speed of grow of tumors, and the degree of dissemination of the neoplastic process. In most 
cases the course of the illness is subacute to chronic, initiated by a marked loss of weight and 
appetite, and weakness. Clinical signs most often observed are decreased milk production, 
lymphadenopathy, and posterior paresis. Once the clinical signs of the illness are evident, the 
course is rapid and invariably culminate in death [77].
3.2. Transmission of BLV and economic impact of the infection
As cell‐free virus is rarely detected in vivo, most susceptible cattle become infected by exposure 
to infected lymphocytes. Vertical transmission may occur in utero but is infrequent. The main 
biologic fluids that contain sufficient infected lymphocytes to transmit the infection are the blood, 
colostrum, and milk. Other fluids such as saliva, semen, urine, and nasal secretions, while poten‐
tially infectious, have not been demonstrated to transmit the infection in natural conditions [78].
Under general or standard production conditions, the risk of horizontal transmission is aug‐
mented by management practices or procedures involving blood transfer such as gouge 
dehorning, ear tagging or tattooing, blood extraction, and rectal palpation, using shared or 
not properly disinfected instruments [78]. This risk is augmented when contaminating blood 
comes from cattle with persistent lymphocytosis [79]. The use of natural service (i.e., bulls) to 
breed heifers was also identified as a risk factor for augmented prevalence of BLV infection 
compared to artificial insemination [80].
Evidence has been reported on the role of bloodsucking insects, such as stable flies, horn flies, 
and tabanids in the transmission of BLV [81]. Furthermore, the lack of insect control program 
has been recognized as a risk factor for BLV infection [82, 83]. In warm regions, the animals 
may be exposed to a high density of hematophagous insects that continuously fed on them; 
hence, the control of bloodsucking insects by pesticides has been reported to prevent the 
transmission in a model farm [84]. Both colostrum and milk from BLV‐positive cows contain 
infected lymphocytes, and evidence exists for the transmission of BLV to calves by feeding 
bulk milk, a common practice in dairy herds [78, 85]. The rate of transmission attributable to 
this route has been estimated to be 6–16 % under natural conditions. On the other hand, feed‐
ing colostrum from infected dams, which contains high titers of antiviral antibodies, seems to 
have a protective role, being the susceptibility of calves dependent on the presence of specific 
antibodies obtained from the dam's colostrums and the age of the calf [78, 86, 87].
Enzootic bovine leucosis causes significant economic losses. The most obvious economic 
losses are due to culling or death due to lymphosarcoma, shortening of lifespan, and loss of 
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production potential. Other indirect losses are related to the costs of control and eradication 
programs and restrictions in the international trade of cattle and their by‐products. Annual 
economic losses to the US dairy industry associated with BLV are estimated to be $285 million 
for producers and $240 million for consumers [80]. The effects of subclinical BLV infection on 
milk production, reproductive performance, longevity, and culling rate are variable. Using 
data from the National Animal Health Monitoring System's 1996 dairy herd study, it was 
found that herds with test‐positive cows produced 218 kg less milk per cow/per year than 
those with no test‐positive cows [88].
There is no treatment for BLV infection or its associated disease. The possibility of a vaccine 
for protection against BLV has been explored (reviewed in [89]). A BLV vaccine would have to 
be noninfectious and non‐oncogenic and should not interfere with the serological tests com‐
monly used to detect infection [77].
3.3. Phenotypes associated with resistance and susceptibility in BLV infection
Studies from our laboratory have gone further into the characterization of BLV‐infected, 
hematologically normal cattle (i.e., those animals that do not develop PL). Based on the 
proviral load in the peripheral blood and antibodies against BLV major proteins, we could 
describe two defined phenotypes in BLV‐infected cattle. Proviral load was determined in 
DNA from peripheral blood leukocytes by a very sensitive nested PCR or a semiquanti‐
tative PCR [90], while antibody titers were measured against the BLV major antigens by 
ELISA [90, 91].
One group of animals is characterized by high proviral load (HPL) in peripheral blood 
(>100,000 BLV proviral copies/μg of DNA) and high antibody titers against the envelope 
protein of BLV of 51 kDa (BLVgp51). On the other hand, the remaining non‐PL animals 
harbor an exiguous number of infected lymphocytes in the peripheral blood, almost unde‐
tectable by the molecular methods currently used (PCR and real‐time PCR); we have termed 
this group low proviral load (LPL) cattle. These cattle develop low titers of antiviral anti‐
bodies against BLVgp51, while antibodies against BLVp24, the main core protein of BLV, 
are undetectable in the majority of LPL cattle or developed at very low titers. The follow‐up 
of HPL and LPL cattle showed that each phenotype was maintained throughout, at least, 
a 1.5‐year period. The characterization of PL cattle in terms of proviral load and titers of 
antibodies against BLV showed no significant differences with non‐PL HPL cattle. Cattle 
with LPL profile represented about 60 % of hematologically normal cattle and 40 % of all 
BLV‐infected cattle [92]. Table 1 shows the main parameters that characterize both HPL and 
LPL infection phenotypes.
As virtually all cattle infected with BLV will continuously have antibodies against the virion 
proteins in their serum, serologic tests are commonly used for diagnosis of BLV infection in 
cattle > 6 months old. PL cattle and non‐PL HPL cattle have high titers of antibodies against 
the major viral antigens, and then, they are easily classified as positive by means of the major‐
ity of serological tests in the market (mainly ELISAs or immunodiffusion tests). On the other 
hand, antibody titers against BLVgp51 are lower in most LPL animals compared to HPL cattle, 
and antibodies against BLVp24 are at very low titers or undetectable in most serum samples 
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from LPL cattle. Hence, sensitivity of serological tests is decisive in their capacity to detect 
LPL animals. We have consistently detected LPL animals with a highly sensitive blocking 
ELISA developed in our lab, designated ELISA 108. This method detects antibodies against 
an immunodominant conformational epitope of the BLVgp51 at low titers. Other serological 
methods using BLVgp51 as antigen may also detect BLV‐infected LPL animals, provided that 
they are sensitive enough. This is not the case of agar gel immunodiffusion (AGID) test com‐
mercialized in Argentina. On the other hand, serological tests using BLVp24 as antigen would 
not be able to detect LPL cattle in most cases.
We inoculated sheep with blood from LPL cattle to give further evidence of infection. This was an 
easily available alternative for the amplification and study of the BLV strain [93]. As the number 
of infected lymphocytes in peripheral blood from LPL cattle is extremely low, it was necessary 
to inoculate a large volume of blood to obtain the minimal quantity of infected lymphocytes to 
transmit the infection. The minimal dose necessary to infect sheep is about 926 BLV‐infected lym‐
phocytes [94]. One microliter of blood from a HPL cow was enough to infect lambs. In contrast, 
blood from LPL cattle also infected lambs, but 100 ml of blood was necessary to infect the ovine 
host. In order to determine if differences in the observed phenotypes could be attributable to dif‐
ferences at the nucleotide level between strains, a fragment of the env gene was amplified from 
infected lambs by nested PCR and sequenced. No mutations in the env gene that could be attrib‐
utable to the passage from cow to lamb were detected. When comparing a 400‐bp sequence from 
the env gene from six LPL and six HPL strains, no mutations were found that could be associated 
with any particular phenotype, strengthening the hypothesis that the development of each phe‐
notype could be associated primarily with some genetic or epigenetic property of the host [95].
As LPL cattle maintained their phenotype for prolonged periods of time, without develop‐
ing any hematologic or pathologic condition, it is proposed that these animals are naturally 
resistant to BLV replication.
3.4. Association of BLV phenotypes to polymorphisms at the major histocompatibility 
complex
Early observations on the aggregation of lymphoma/leukemia or PL in certain BLV‐infected 
families, but not in others, suggested that host genetic factors were involved in the  development 
BLV infection 
phenotype
Hematological status Proviral loada Antibody titer
BLVgp51 BLVp24
HPL PL ≥100,000 400 to ≥ 6400 50–800
HPL Non PL ≥100,000 400 to ≥ 6400 Seronegative to 400
LPL Non PL ≤100 2–1600 Seronegative to 50
Proviral load was determined by semiquantitative PCR in DNA extracted from the peripheral blood. Antibody titers 
against BLVgp51 and BLV p24 were determined in plasma samples by ELISA.
a Proviral copies/μg DNA
Adapted from Juliarena et al. [92]
Table 1. Characterization of HPL and LPL phenotypes in terms of proviral load in the peripheral blood, hematological 
status, and antibody titer against BLVgp51 and BLVp24.
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of these conditions [96]. There were also indications that host genetic factors influenced the 
susceptibility to one condition or the other independently [97].
Studies on the relationship between BLV infection and bovine MHC (BoLA) revealed an asso‐
ciation between serologically determined BoLA‐A class I antigens and resistance and suscep‐
tibility to B‐cell lymphocytosis in Shorthorn cattle [98], Holstein [99, 100], and other breeds 
[101]. However, these associations were relatively weak at the population level, and different 
BoLA‐A alleles had significant effects in different breeds [102]. Subsequently, it was shown that 
resistance and susceptibility to PL map more closely to MHC class II BoLA‐DRB3 gene than to 
BoLA‐A locus [56, 103]. A peptide motif named ER, which is present in BoLA‐DRB3 alleles *11, 
*23, and *28, was associated with resistance to PL in BLV‐infected cattle. Resistance appears to 
be dependent upon the presence of the polar amino acids Glu‐Arg at positions 70–71 within a 
highly polymorphic segment of the peptide‐binding region [56]. This contributes to the puta‐
tive peptide‐binding specificity of the molecule at the β1 domain [11]. It is believed that the 
allelic differences influence the binding and orientation of viral peptides [104], thus deter‐
mining allele specificity differences in the spectrum of peptides presented to the immune 
system. These differences may have important consequences for infection resistance [105]. 
Furthermore, it was shown that BoLA‐DRB3 alleles encoding Glu, Arg, and Val at positions 74, 
77, and 78 of the BoLA‐DRβ chain, respectively, might be related to tumor development resis‐
tance [106]. Moreover, evidence was presented that BLV‐infected cattle selected for the pres‐
ence of the DRB3*11 allele carry less infected lymphocytes than other infected animals [107].
Based on these previous reports found in literature about the association of BoLA polymor‐
phisms with PL development or the number of BLV‐infected lymphocytes in peripheral blood 
up to 1998, we decided to evaluate the association between the BLV infection phenotypes 
described above and BoLA‐DRB3 genotype. Various molecular methods were used for the 
genotyping of BoLA‐DRB3 exon 2 (the only one expressed from BoLA‐DRB3 gene). In a first 
instance, we used the PCR‐restriction fragment length polymorphism (PCR‐RFLP) method, 
which can differentiate only 57 different alleles (designated by the nomenclature based on 
this method). The PCR‐sequence specific oligonucleotides polymorphisms (PCR‐SSOP) is an 
alternative method which is more specific, allowing the identification of 104 alleles from the 
130 described by sequencing, and defines the alleles according to the nomenclature adopted 
by the International Society for Animal Genetics [34].
Xu et al. [56] described a correlation between BoLA‐DRB3*11 allele and PL in Holstein cattle. The 
allele *11 (identifiable by PCR‐RFLP) can be differentiated into two variants: BoLA‐DRB3*0901 
and BoLA‐DRB3*0902 by using PCR‐SSOP or by sequencing. By studying the genotype of 230 
BLV‐infected cattle belonging to seven dairy herds, we found that allele BoLA‐DRB3*11 was 
significantly associated with the LPL phenotype (odds ratio (OR) = 5.82; p < 0.0001); however, 
the subtype BoLA‐DRB3*0902, which is the most prevalent subtype of allele *11 in our popu‐
lation, showed a stronger association with the LPL phenotype (OR = 8.24; p < 0.0001) than 
allele *11 itself. Allele BoLA‐DRB3*1701 also showed significant association with LPL profile 
(OR = 3.46; p < 0.0055). The HPL phenotype was significantly associated (OR = 0.36; p < 0.0005) 
with only one allele: BoLA‐DRB3*1501 (allele *16 as determined by PCR‐RFLP). According to 
these associations, the DRB3 alleles were assigned to three categories: resistant (R) if the allele 
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was associated with LPL phenotype, susceptible (S) if the allele was associated with HPL phe‐
notype, and neutral (N) if the allele was not associated with any phenotype [53].
It is concluded that the host genetic background influences BLV infection phenotype develop‐
ment and that allele BoLA‐DRB3*0902 appears to be, up to now, the best candidate marker 
of BLV resistance in Argentinean Holstein cattle. The penetrance of BoLA‐DRB*0902 allele 
for the LPL phenotype is notably high compared to the penetrance of MHC alleles in other 
systems which, in general, is much lower (about 10 %). More than 80 % of cattle carrying the 
BoLA‐DRB3*0902 allele develop LPL when naturally or experimentally infected with BLV [53, 
108, 109]. However, only one third of LPL cattle harbors the BoLA‐DRB3*0902 allele [53]. This 
finding suggests that other genetic or epigenetic factors might be involved in the regulation 
of BLV proviral load.
3.5. Influence of resistance‐associated alleles on specific immune response and infectivity 
of LPL cattle
Cattle with LPL phenotype were grouped according to the presence of alleles associated to the 
LPL phenotype (i.e., R alleles *0902 and *1701) in their genotype. Table 2 shows the average 
anti‐BLVgp51 antibody titer for each group and the resulting classification of cattle according 
to the level of antibody response against the main envelope glycoprotein of BLV. The R alleles 
BoLA‐DRB3*0902 and BoLA‐DRB3*1701 were significantly associated with low antibody titers 
against both BLVgp51 and BLVp24 [110]. Important differences were observed in the infec‐
tivity of the blood from cattle in each group, as determined by the sheep bioassay. While all 
lambs inoculated with blood from LPL cattle not harboring any allele R or harboring one R 
allele (*0902 or *1701) in heterozygosis were infected, only one from six lambs inoculated 
with 100 ml of blood from LPL cattle with R/R genotype acquired the infection. From these 
results, it seems that LPL cattle carrying two R alleles have an increased ability to restrict BLV 
replication [108].
It is unlikely that BLV‐infected LPL cattle would be a source of infection for BLV‐free animals, 
as large volumes of blood are never exchanged between animals under usual management 
practices and natural breeding in dairy farms.
BoLA‐DRB3 genotype n BLVgp51 antibody 
titera
Classificationb Infectivityc
Without allele R 54 662.3 Medium or high 
responders
6/6
Allele R in 
heterozygosis
34 344.3 Medium or low 
responders
4/4
Allele R in 
homozygosis
9 275.0 Extremely low 
responders
1/6
a Average
b Classification was done according to the level of antibody titer against BLVgp51.
c Infectivity was assessed by inoculating 100 ml of blood in lambs. Number of lambs infected/number of lambs inoculated
Table 2. Grouping of BLV‐infected cattle with LPL phenotype, according to the presence of alleles associated with 
resistance (R) in their genotype.
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3.6. Strategies to control BLV infection
BLV control and eradication programs based on culling infected animals have been accepted 
and implemented successfully in several western European countries. In dairy farms with low 
prevalence of BLV infection, the cost of implementing these programs is less than the total cost 
caused by BLV infection [111]. However, in herds where the prevalence of infection is high, 
the feasibility of implementation of these programs depends on the official compensation to 
producers for the removal of BLV‐positive animals. In Argentina, not only there is no official 
BLV control program, but official apathy since the 1970s has been the best ally for the lush 
spread of BLV in all dairy regions, including Patagonia. By 1995, the failure of the voluntary 
control program of BLV proposed by the National Authority in Animal Heath (Resolution 
337/94 from SENASA) was the indicator that Argentina had lost the opportunity to reduce the 
spread of BLV by means of serological testing and culling and to protect the scarce herds and 
regions that were still free of BLV.
To limit the spread of BLV, infected cattle are often eliminated on the basis of their risk of 
transmitting the infection to other cattle. Among BLV‐infected cattle, those with PL are con‐
sidered the most efficient transmitters because they harbor a high percentage of infected lym‐
phocytes in peripheral blood [112] and consequently have HPL [107]. Furthermore, although 
not all PL animals develop lymphosarcoma, in approximately two thirds of cases, neoplasia 
is preceded by PL. The application of control plans based on hematological tests and elimina‐
tion of PL animals has failed to control not only BLV infection but also the associated lympho‐
sarcoma. In 1959, Denmark implemented an eradication program based on the occurrence of 
clinical lymphosarcoma and the identification of PL cattle by using the Bendixen hematologi‐
cal keys [113]. Affected herds were quarantined, and indemnity was offered to induce owners 
to have slaughtered their entire herd. This herd‐slaughter policy was continued until 1982. 
However, when the serological tests were introduced, some herds which were classified as 
leucosis‐free based on the hematological keys were found to be infected [77]. One of the major 
causes of this failure was probably due to the presence of HPL animals that do not present 
PL. These non‐PL HPL animals are as efficient as PL cattle to transmit the BLV, and it is likely 
that the animals that develop lymphosarcoma without a previous stage of PL also belong to 
this group of cattle. Therefore, the corrective management based in classification of animals 
according to HPL and LPL phenotypes should be safer that the plan based on traditional 
hematological classification (PL and non‐PL).
4. Genetic selection of resistant animals
The genetic selection of resistant animals would be an efficient strategy for controlling the 
spread of BLV in the host and, therefore, to reduce the occurrence of clinical lymphosarcoma. 
We have shown that, in the Holstein breed, the BoLA‐DRB3*0902 allele is the best molecular 
marker for the selection of resistant animals. The BoLA‐DRB3 gene is highly polymorphic, 
with 130 alleles described so far. The allele frequency of the *0902 allele is relatively high 
(5–10 %) at the population level; therefore, it is possible to easily increase its frequency by 
directed crossbreeding or artificial insemination. At the herd level, it is essential that these 
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resistant animals disrupt the transmission of BLV to uninfected animals. Hence, the effective‐
ness of this procedure would depend on the accuracy of the premise that BLV‐infected LPL 
cattle harboring BoLA‐DRB3*0902 marker do not transmit the virus to BLV‐negative cattle 
under normal breeding conditions in commercial dairy herds.
4.1. The proof of concept
In order to test this premise, an experiment was carried out in a commercial dairy herd located 
in a subtropical region of Argentina, having extreme environmental conditions (experimental 
dairy herd). In the experimental dairy herd, BLV‐free and BLV‐infected LPL‐BoLA‐DRB3*0902 
animals cohabited for 20 months. This period included two summers during which BLV‐
infected and BLV‐uninfected cattle were exposed to heat stress and to a high density and 
varied population of bloodsucking insects that continuously fed on the animals. As is usual 
in any commercial dairy herd, the cattle population was dynamic, and necessary replace‐
ments were made according to production needs and milk production requirements, which 
were within expected parameters in the region. Nevertheless, only previously characterized 
animals (BLV‐free or BLV‐infected LPL‐BoLA‐DRB3*0902 animals) were introduced to the 
experimental herd. Normal management practices and production requirements were main‐
tained in the herd. We examined the spread of BLV in the experimental herd and also in 
other four local commercial herds in which no selection of cattle was made. The incidence 
rates observed in these four herds were between 0.06 and 0.17 cases per 100 cattle‐days. The 
observed incidence rate explains the increase of prevalence registered in the region from 
2002–2003 to 2010–2011 [114, 115]. In contrast, in the experimental herd, no new BLV‐infected 
animals were detected, and as a corollary, the incidence rate was zero. These results indicate 
that LPL‐BoLA‐DRB3*0902 cattle do indeed disrupt the BLV transmission chain and that selec‐
tion of cattle carrying this allele represents a promising approach to control the virus [116].
The results presented are the base of a BLV control strategy based on genetic selection of 
resistant animals, using BoLA‐DRB3*0902 allele as molecular selection marker. The idea is 
to gradually replace HPL cattle in high‐prevalence herds with BoLA‐DRB3.2*0902 harboring 
cattle. The expected increase in herd resistance to BLV would block the transmission of BLV, 
thereby counteracting the main epidemiological advantage of BLV, i.e., its transmission.
4.2. Influence of resistance and susceptibility‐associated alleles on other health and 
productive traits
Due to the relevant role of MHC genes in the immune response, a potential risk in expand‐
ing or segregating BoLA‐selected populations of cattle is that it might increase susceptibil‐
ity to other common viruses. A special concern is raised by the strong association found 
between BoLA‐DRB3*0902 and BoLA‐DRB3*1701 and low antibody titer against major BLV 
structural proteins. This phenomenon, which may depend on host genetic factors, might 
influence the host response to other viruses requiring, unlike BLV, strong and long‐ lasting 
humoral immune response in order to prevent infection. Therefore, we determined the 
association between antibody titer against three widespread bovine viruses and BoLA‐
DRB3 gene polymorphism. These three viruses, the bovine viral diarrhea virus (BVDV), the 
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bovine  herpesvirus type 1 (BHV‐1), and the foot and mouth disease virus (FMDV), which 
are spread in most or several countries all over the world, cause diseases and syndromes 
that negatively affect the economic performance of the dairy and beef cattle industries. 
Protection against these three viruses is achieved when high titers of neutralizing antibodies 
are raised. No association was found between neutralizing antibody titers against FMDV, 
BVDV, or BHV‐1 and polymorphism of the BoLA‐DRB3 gene [110]. Therefore, increasing 
BoLA‐selected BLV‐resistant cattle or segregating BoLA alleles associated with BLV suscep‐
tibility would not affect the resistance or susceptibility to BVDV, BHV‐1, or FMDV infection. 
Further studies involving other parameters, such as the persistence or viral load status con‐
cerning FMDV, BHV‐1, and BVDV, and their association to BoLA‐DRB3 polymorphism, are 
needed. These parameters would probably represent a better indicator of resistance against 
the aforementioned viruses.
Preliminary data obtained from endemic areas showed that there is no association between 
the allele BoLA‐DRB3*0902 and infection with BVDV, bovine herpesvirus type 4 (BoHV‐4), 
and Neospora caninum [117]. A recent study also showed no association of the aforementioned 
allele with infection by Mycobacterium bovis (M. bovis), although this observation should be 
confirmed in a more extensive study. Moreover, it was shown that the ability of cattle carry‐
ing resistance‐associated marker to control BLV and to progress to LPL phenotype was not 
altered by M. bovis coinfection [118].
Alleles BoLA‐DRB3*0902 (or *11 as determined by PCR‐RFLP) and BoLA‐DRB3*1701 (or *12 
as determined by PCR‐RFLP) are associated with resistance to intramammary infection and 
higher production traits [119, 120]. Thus, expanding the population of cattle harboring these 
alleles in order to control BLV infection would also increase resistance to mastitis. When tar‐
geting BLV control by means of genetic selection, animals carrying alleles associated to sus‐
ceptibility, such as BoLA‐DRB3*1501, are not desired. This allele did not show association 
with antibody titer against FMDV, BHV‐1, or BVDV [110] nor it affected productive traits [45]. 
BoLA‐DRB3*1501 has been previously associated with high somatic cell score (SCS) in milk 
[44, 121]. Thus, if we are to decrease the frequency of the BoLA‐DRB3*1501 allele in order to 
control BLV infection, the SCS of the cattle population would additionally be reduced. It has 
been reported that BLV infection is frequently associated with an increase in SCS [122–124]. It 
is conceivable that this association derives from host genetic susceptibility to both conditions, 
probably conferred by BoLA‐DRB3*1501 allele.
Up to date, the presence of BoLA‐DRB3*0902 allele in the genotype of Holstein cattle neither 
has it been associated with susceptibility to any infectious disease nor with negative effects on 
production or reproductive traits.
4.3. Concluding remarks
We have proposed a BLV control and eradication program based on genetic selection. This 
plan is based on two main premises: (1) the development of LPL phenotype (BLV‐resistant 
cattle) can be predicted by a marker (BoLA‐DRB3*0902) that is transmitted to the progeny 
by controlled crossbreeding, and (2) BLV‐infected cattle with LPL phenotype do not transmit 
the virus.
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The BoLA‐DRB3*0902 heterozygous animals comply these two premises. This marker has 
a penetrance of 82 % and its pattern of inheritance is codominant. BoLA‐DRB3*0902 ani‐
mals with LPL phenotype did not transmit the infection at herd level in natural conditions, 
and under experimental conditions, it was required to inoculate a large volume of blood 
to infect sheep. Finally, up the date, the BoLA‐DRB3*0902 allele has not been associated 
with susceptibility to other infectious agents, nor has it affected production or reproduc‐
tion traits.
The BLV control and eradication program has been designed in two steps: as the first step, 
HPL cattle should be replaced by cattle harboring the BoLA‐DRB3*0902 marker. Once cull‐
ing of HPL animals has been completed, as the second step, LPL cattle should be replaced 
by BLV‐negative cattle. The selected animals for the replacement in the first step should 
carry the BoLA‐DRB3*0902 allele in heterozygosis with other alleles not associated with any 
BLV phenotype [53]. Finally, it should be mentioned that a potential risk exists in expanding 
or segregating BoLA genotype‐selected populations, which might increase susceptibility to 
other infectious agents.
5. Conclusions
Among the diversity of genes associated to disease resistance, MHC genes are particu‐
larly interesting as they are associated with resistance and susceptibility to a wide range of 
 diseases. Some of these diseases produce important economic losses in livestock. Genetic 
selection of resistant animals emerges as a natural strategy for the control of infectious 
diseases, especially when there is no other alternative of control or prevention, as vaccines.
The control of BLV infection based on genetic selection of resistant cattle is presented as a 
model that may potentially be replicated in other infectious diseases affecting livestock.
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